{"pmid":32338708,"title":"Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19.","text":["Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19.","BACKGROUND: There are many pharmacologic therapies that are being used or considered for treatment of COVID-19. There is a need for frequently updated practice guidelines on their use, based on critical evaluation of rapidly emerging literature. OBJECTIVE: Develop evidence-based rapid guidelines intended to support patients, clinicians and other health-care professionals in their decisions about treatment and management of patients with COVID-19. METHODS: IDSA formed a multidisciplinary guideline panel of infectious disease clinicians, pharmacists, and methodologists with varied areas of expertise. Process followed a rapid recommendation checklist. The panel prioritized questions and outcomes. Then a systematic review of the peer-reviewed and grey literature was conducted. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to assess the certainty of evidence and make recommendations. RESULTS: The IDSA guideline panel agreed on 7 treatment recommendations and provided narrative summaries of other treatments undergoing evaluations. CONCLUSIONS: The panel expressed the overarching goal that patients be recruited into ongoing trials, which would provide much needed evidence on the efficacy and safety of various therapies for COVID-19, given that we could not make a determination whether the benefits outweigh harms for most treatments.","Clin Infect Dis","Bhimraj, Adarsh","Morgan, Rebecca L","Shumaker, Amy Hirsch","Lavergne, Valery","Baden, Lindsey","Cheng, Vincent Chi-Chung","Edwards, Kathryn M","Gandhi, Rajesh","Muller, William J","O'Horo, John C","Shoham, Shmuel","Murad, M Hassan","Mustafa, Reem A","Sultan, Shahnaz","Falck-Ytter, Yngve","32338708"],"abstract":["BACKGROUND: There are many pharmacologic therapies that are being used or considered for treatment of COVID-19. There is a need for frequently updated practice guidelines on their use, based on critical evaluation of rapidly emerging literature. OBJECTIVE: Develop evidence-based rapid guidelines intended to support patients, clinicians and other health-care professionals in their decisions about treatment and management of patients with COVID-19. METHODS: IDSA formed a multidisciplinary guideline panel of infectious disease clinicians, pharmacists, and methodologists with varied areas of expertise. Process followed a rapid recommendation checklist. The panel prioritized questions and outcomes. Then a systematic review of the peer-reviewed and grey literature was conducted. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to assess the certainty of evidence and make recommendations. RESULTS: The IDSA guideline panel agreed on 7 treatment recommendations and provided narrative summaries of other treatments undergoing evaluations. CONCLUSIONS: The panel expressed the overarching goal that patients be recruited into ongoing trials, which would provide much needed evidence on the efficacy and safety of various therapies for COVID-19, given that we could not make a determination whether the benefits outweigh harms for most treatments."],"journal":"Clin Infect Dis","authors":["Bhimraj, Adarsh","Morgan, Rebecca L","Shumaker, Amy Hirsch","Lavergne, Valery","Baden, Lindsey","Cheng, Vincent Chi-Chung","Edwards, Kathryn M","Gandhi, Rajesh","Muller, William J","O'Horo, John C","Shoham, Shmuel","Murad, M Hassan","Mustafa, Reem A","Sultan, Shahnaz","Falck-Ytter, Yngve"],"date":"2020-04-28T11:00:00Z","year":2020,"_id":"32338708","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1093/cid/ciaa478","topics":["Treatment"],"weight":1,"_version_":1665264685614628865,"score":8.574329,"similar":[{"pmid":32224769,"title":"Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19).","text":["Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19).","BACKGROUND: The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of a rapidly spreading illness, Coronavirus Disease 2019 (COVID-19), affecting thousands of people around the world. Urgent guidance for clinicians caring for the sickest of these patients is needed. METHODS: We formed a panel of 36 experts from 12 countries. All panel members completed the World Health Organization conflict of interest disclosure form. The panel proposed 53 questions that are relevant to the management of COVID-19 in the ICU. We searched the literature for direct and indirect evidence on the management of COVID-19 in critically ill patients in the ICU. We identified relevant and recent systematic reviews on most questions relating to supportive care. We assessed the certainty in the evidence using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach, then generated recommendations based on the balance between benefit and harm, resource and cost implications, equity, and feasibility. Recommendations were either strong or weak, or in the form of best practice recommendations. RESULTS: The Surviving Sepsis Campaign COVID-19 panel issued 54 statements, of which four are best practice statements, nine are strong recommendations, and 35 are weak recommendations. No recommendation was provided for six questions. The topics were: 1) infection control, 2) laboratory diagnosis and specimens, 3) hemodynamic support, 4) ventilatory support, and 5) COVID-19 therapy. CONCLUSION: The Surviving Sepsis Campaign COVID-19 panel issued several recommendations to help support healthcare workers caring for critically ill ICU patients with COVID-19. When available, we will provide new evidence in further releases of these guidelines.","Crit Care Med","Alhazzani, Waleed","Moller, Morten Hylander","Arabi, Yaseen M","Loeb, Mark","Gong, Michelle Ng","Fan, Eddy","Oczkowski, Simon","Levy, Mitchell M","Derde, Lennie","Dzierba, Amy","Du, Bin","Aboodi, Michael","Wunsch, Hannah","Cecconi, Maurizio","Koh, Younsuck","Chertow, Daniel S","Maitland, Kathryn","Alshamsi, Fayez","Belley-Cote, Emilie","Greco, Massimiliano","Laundy, Matthew","Morgan, Jill S","Kesecioglu, Jozef","McGeer, Allison","Mermel, Leonard","Mammen, Manoj J","Alexander, Paul E","Arrington, Amy","Centofanti, John E","Citerio, Giuseppe","Baw, Bandar","Memish, Ziad A","Hammond, Naomi","Hayden, Frederick G","Evans, Laura","Rhodes, Andrew","32224769"],"abstract":["BACKGROUND: The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of a rapidly spreading illness, Coronavirus Disease 2019 (COVID-19), affecting thousands of people around the world. Urgent guidance for clinicians caring for the sickest of these patients is needed. METHODS: We formed a panel of 36 experts from 12 countries. All panel members completed the World Health Organization conflict of interest disclosure form. The panel proposed 53 questions that are relevant to the management of COVID-19 in the ICU. We searched the literature for direct and indirect evidence on the management of COVID-19 in critically ill patients in the ICU. We identified relevant and recent systematic reviews on most questions relating to supportive care. We assessed the certainty in the evidence using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach, then generated recommendations based on the balance between benefit and harm, resource and cost implications, equity, and feasibility. Recommendations were either strong or weak, or in the form of best practice recommendations. RESULTS: The Surviving Sepsis Campaign COVID-19 panel issued 54 statements, of which four are best practice statements, nine are strong recommendations, and 35 are weak recommendations. No recommendation was provided for six questions. The topics were: 1) infection control, 2) laboratory diagnosis and specimens, 3) hemodynamic support, 4) ventilatory support, and 5) COVID-19 therapy. CONCLUSION: The Surviving Sepsis Campaign COVID-19 panel issued several recommendations to help support healthcare workers caring for critically ill ICU patients with COVID-19. When available, we will provide new evidence in further releases of these guidelines."],"journal":"Crit Care Med","authors":["Alhazzani, Waleed","Moller, Morten Hylander","Arabi, Yaseen M","Loeb, Mark","Gong, Michelle Ng","Fan, Eddy","Oczkowski, Simon","Levy, Mitchell M","Derde, Lennie","Dzierba, Amy","Du, Bin","Aboodi, Michael","Wunsch, Hannah","Cecconi, Maurizio","Koh, Younsuck","Chertow, Daniel S","Maitland, Kathryn","Alshamsi, Fayez","Belley-Cote, Emilie","Greco, Massimiliano","Laundy, Matthew","Morgan, Jill S","Kesecioglu, Jozef","McGeer, Allison","Mermel, Leonard","Mammen, Manoj J","Alexander, Paul E","Arrington, Amy","Centofanti, John E","Citerio, Giuseppe","Baw, Bandar","Memish, Ziad A","Hammond, Naomi","Hayden, Frederick G","Evans, Laura","Rhodes, Andrew"],"date":"2020-04-01T11:00:00Z","year":2020,"_id":"32224769","week":"202014|Mar 30 - Apr 05","doi":"10.1097/CCM.0000000000004363","source":"PubMed","topics":["Prevention","Diagnosis","Treatment"],"weight":1,"_version_":1664640912740843520,"score":601.6617},{"pmid":32222812,"pmcid":"PMC7101866","title":"Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19).","text":["Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19).","BACKGROUND: The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of a rapidly spreading illness, Coronavirus Disease 2019 (COVID-19), affecting thousands of people around the world. Urgent guidance for clinicians caring for the sickest of these patients is needed. METHODS: We formed a panel of 36 experts from 12 countries. All panel members completed the World Health Organization conflict of interest disclosure form. The panel proposed 53 questions that are relevant to the management of COVID-19 in the ICU. We searched the literature for direct and indirect evidence on the management of COVID-19 in critically ill patients in the ICU. We identified relevant and recent systematic reviews on most questions relating to supportive care. We assessed the certainty in the evidence using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach, then generated recommendations based on the balance between benefit and harm, resource and cost implications, equity, and feasibility. Recommendations were either strong or weak, or in the form of best practice recommendations. RESULTS: The Surviving Sepsis Campaign COVID-19 panel issued 54 statements, of which 4 are best practice statements, 9 are strong recommendations, and 35 are weak recommendations. No recommendation was provided for 6 questions. The topics were: (1) infection control, (2) laboratory diagnosis and specimens, (3) hemodynamic support, (4) ventilatory support, and (5) COVID-19 therapy. CONCLUSION: The Surviving Sepsis Campaign COVID-19 panel issued several recommendations to help support healthcare workers caring for critically ill ICU patients with COVID-19. When available, we will provide new recommendations in further releases of these guidelines.","Intensive Care Med","Alhazzani, Waleed","Moller, Morten Hylander","Arabi, Yaseen M","Loeb, Mark","Gong, Michelle Ng","Fan, Eddy","Oczkowski, Simon","Levy, Mitchell M","Derde, Lennie","Dzierba, Amy","Du, Bin","Aboodi, Michael","Wunsch, Hannah","Cecconi, Maurizio","Koh, Younsuck","Chertow, Daniel S","Maitland, Kathryn","Alshamsi, Fayez","Belley-Cote, Emilie","Greco, Massimiliano","Laundy, Matthew","Morgan, Jill S","Kesecioglu, Jozef","McGeer, Allison","Mermel, Leonard","Mammen, Manoj J","Alexander, Paul E","Arrington, Amy","Centofanti, John E","Citerio, Giuseppe","Baw, Bandar","Memish, Ziad A","Hammond, Naomi","Hayden, Frederick G","Evans, Laura","Rhodes, Andrew","32222812"],"abstract":["BACKGROUND: The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of a rapidly spreading illness, Coronavirus Disease 2019 (COVID-19), affecting thousands of people around the world. Urgent guidance for clinicians caring for the sickest of these patients is needed. METHODS: We formed a panel of 36 experts from 12 countries. All panel members completed the World Health Organization conflict of interest disclosure form. The panel proposed 53 questions that are relevant to the management of COVID-19 in the ICU. We searched the literature for direct and indirect evidence on the management of COVID-19 in critically ill patients in the ICU. We identified relevant and recent systematic reviews on most questions relating to supportive care. We assessed the certainty in the evidence using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach, then generated recommendations based on the balance between benefit and harm, resource and cost implications, equity, and feasibility. Recommendations were either strong or weak, or in the form of best practice recommendations. RESULTS: The Surviving Sepsis Campaign COVID-19 panel issued 54 statements, of which 4 are best practice statements, 9 are strong recommendations, and 35 are weak recommendations. No recommendation was provided for 6 questions. The topics were: (1) infection control, (2) laboratory diagnosis and specimens, (3) hemodynamic support, (4) ventilatory support, and (5) COVID-19 therapy. CONCLUSION: The Surviving Sepsis Campaign COVID-19 panel issued several recommendations to help support healthcare workers caring for critically ill ICU patients with COVID-19. When available, we will provide new recommendations in further releases of these guidelines."],"journal":"Intensive Care Med","authors":["Alhazzani, Waleed","Moller, Morten Hylander","Arabi, Yaseen M","Loeb, Mark","Gong, Michelle Ng","Fan, Eddy","Oczkowski, Simon","Levy, Mitchell M","Derde, Lennie","Dzierba, Amy","Du, Bin","Aboodi, Michael","Wunsch, Hannah","Cecconi, Maurizio","Koh, Younsuck","Chertow, Daniel S","Maitland, Kathryn","Alshamsi, Fayez","Belley-Cote, Emilie","Greco, Massimiliano","Laundy, Matthew","Morgan, Jill S","Kesecioglu, Jozef","McGeer, Allison","Mermel, Leonard","Mammen, Manoj J","Alexander, Paul E","Arrington, Amy","Centofanti, John E","Citerio, Giuseppe","Baw, Bandar","Memish, Ziad A","Hammond, Naomi","Hayden, Frederick G","Evans, Laura","Rhodes, Andrew"],"date":"2020-03-31T11:00:00Z","year":2020,"_id":"32222812","week":"202014|Mar 30 - Apr 05","doi":"10.1007/s00134-020-06022-5","keywords":["COVID-19","Clinical practice guidelines","Coronavirus","Critical illness","SARS CoV-2"],"source":"PubMed","topics":["Diagnosis","Treatment"],"weight":1,"_version_":1663352135206567938,"score":599.9964},{"pmid":32238615,"title":"Perinatal-Neonatal Management of COVID-19 Infection - Guidelines of the Federation of Obstetric and Gynecological Societies of India (FOGSI), National Neonatology Forum of India (NNF), and Indian Academy of Pediatrics (IAP).","text":["Perinatal-Neonatal Management of COVID-19 Infection - Guidelines of the Federation of Obstetric and Gynecological Societies of India (FOGSI), National Neonatology Forum of India (NNF), and Indian Academy of Pediatrics (IAP).","JUSTIFICATION: During the current rapidly evolving pandemic of COVID-19 infection, pregnant women with suspected or confirmed COVID-19 and their newborn infants form a special vulnerable group that needs immediate attention. Unlike other elective medical and surgical problems for which care can be deferred during the pandemic, pregnancies and childbirths will continue. Perinatal period poses unique challenges and care of the mother-baby dyads requires special resources for prevention of transmission, diagnosis of infection and providing clinical care during labor, resuscitation and postnatal period. PROCESS: The GRADE approach recommended by the World Health Organization was used to develop the guideline. A Guideline Development Group (GDG) comprising of obstetricians, neonatologists and pediatricians was constituted. The GDG drafted a list of questions which are likely to be faced by clinicians involved in obstetric and neonatal care. An e-survey was carried out amongst a wider group of clinicians to invite more questions and prioritize. Literature search was carried out in PubMed and websites of relevant international and national professional organizations. Existing guidelines, systematic reviews, clinical trials, narrative reviews and other descriptive reports were reviewed. For the practice questions, the evidence was extracted into evidence profiles. The context, resources required, values and preferences were considered for developing the recommendations. OBJECTIVES: To provide recommendations for prevention of transmission, diagnosis of infection and providing clinical care during labor, resuscitation and postnatal period. RECOMMENDATIONS: A set of twenty recommendations are provided under the following broad headings: 1) pregnant women with travel history, clinical suspicion or confirmed COVID-19 infection; 2) neonatal care; 3) prevention and infection control; 4) diagnosis; 5) general questions.","Indian Pediatr","Chawla, Deepak","Chirla, Dinesh","Dalwai, Samir","Deorari, Ashok K","Ganatra, Atul","Gandhi, Alpesh","Kabra, Nandkishor S","Kumar, Praveen","Mittal, Pratima","Parekh, Bakul Jayant","Sankar, M Jeeva","Singhal, Tanu","Sivanandan, Sindhu","Tank, Parikshit","32238615"],"abstract":["JUSTIFICATION: During the current rapidly evolving pandemic of COVID-19 infection, pregnant women with suspected or confirmed COVID-19 and their newborn infants form a special vulnerable group that needs immediate attention. Unlike other elective medical and surgical problems for which care can be deferred during the pandemic, pregnancies and childbirths will continue. Perinatal period poses unique challenges and care of the mother-baby dyads requires special resources for prevention of transmission, diagnosis of infection and providing clinical care during labor, resuscitation and postnatal period. PROCESS: The GRADE approach recommended by the World Health Organization was used to develop the guideline. A Guideline Development Group (GDG) comprising of obstetricians, neonatologists and pediatricians was constituted. The GDG drafted a list of questions which are likely to be faced by clinicians involved in obstetric and neonatal care. An e-survey was carried out amongst a wider group of clinicians to invite more questions and prioritize. Literature search was carried out in PubMed and websites of relevant international and national professional organizations. Existing guidelines, systematic reviews, clinical trials, narrative reviews and other descriptive reports were reviewed. For the practice questions, the evidence was extracted into evidence profiles. The context, resources required, values and preferences were considered for developing the recommendations. OBJECTIVES: To provide recommendations for prevention of transmission, diagnosis of infection and providing clinical care during labor, resuscitation and postnatal period. RECOMMENDATIONS: A set of twenty recommendations are provided under the following broad headings: 1) pregnant women with travel history, clinical suspicion or confirmed COVID-19 infection; 2) neonatal care; 3) prevention and infection control; 4) diagnosis; 5) general questions."],"journal":"Indian Pediatr","authors":["Chawla, Deepak","Chirla, Dinesh","Dalwai, Samir","Deorari, Ashok K","Ganatra, Atul","Gandhi, Alpesh","Kabra, Nandkishor S","Kumar, Praveen","Mittal, Pratima","Parekh, Bakul Jayant","Sankar, M Jeeva","Singhal, Tanu","Sivanandan, Sindhu","Tank, Parikshit"],"date":"2020-04-03T11:00:00Z","year":2020,"_id":"32238615","week":"202014|Mar 30 - Apr 05","source":"PubMed","topics":["Prevention","Diagnosis"],"weight":1,"_version_":1664638354315018240,"score":433.18274},{"pmid":32335067,"title":"Management of Lung Nodules and Lung Cancer Screening During the COVID-19 Pandemic: CHEST Expert Panel Report.","text":["Management of Lung Nodules and Lung Cancer Screening During the COVID-19 Pandemic: CHEST Expert Panel Report.","BACKGROUND: The risks from potential exposure to COVID-19, and resource reallocation that has occurred to combat the pandemic, have altered the balance of benefits and harms that informed current (pre-COVID-19) guideline recommendations for lung cancer screening and lung nodule evaluation. We developed consensus statements to guide clinicians managing lung cancer screening programs and patients with lung nodules during the COVID-19 pandemic. METHODS: An expert panel of 24 members, including pulmonologists (17), thoracic radiologists (5), and thoracic surgeons (2) was formed. The panel was provided with an overview of current evidence, summarized by recent guidelines related to lung cancer screening and lung nodule evaluation. The panel was convened by video teleconference to discuss then vote on statements related to 12 common clinical scenarios. A pre-defined threshold of 70% of panel members voting agree or strongly agree was used to determine if there was a consensus for each statement. Items that may influence decisions were listed as notes to be considered for each scenario. RESULTS: Twelve statements related to baseline and annual lung cancer screening (2), surveillance of a previously detected lung nodule (5), evaluation of intermediate and high risk lung nodules (4), and management of clinical stage I non-small cell lung cancer (1) were developed and modified. All 12 statements were confirmed as consensus statements by voting results. The consensus statements provide guidance about situations where it was felt to be appropriate to delay screening, defer surveillance imaging of lung nodules, and minimize non-urgent interventions during the evaluation of lung nodules and stage I non-small cell lung cancer. CONCLUSIONS: There was consensus that during the COVID-19 pandemic it is appropriate to defer enrollment in lung cancer screening and modify the evaluation of lung nodules due to the added risks from potential exposure and the need for resource reallocation. There are multiple local, regional, and patient related factors that should be considered when applying these statements to individual patient care.","Chest","Mazzone, Peter J","Gould, Michael K","Arenberg, Douglas A","Chen, Alexander C","Choi, Humberto K","Detterbeck, Frank C","Farjah, Farhood","Fong, Kwun M","Iaccarino, Jonathan M","Janes, Samuel M","Kanne, Jeffrey P","Kazerooni, Ella A","MacMahon, Heber","Naidich, David P","Powell, Charles A","Raoof, Suhail","Rivera, M Patricia","Tanner, Nichole T","Tanoue, Lynn K","Tremblay, Alain","Vachani, Anil","White, Charles S","Wiener, Renda Soylemez","Silvestri, Gerard A","32335067"],"abstract":["BACKGROUND: The risks from potential exposure to COVID-19, and resource reallocation that has occurred to combat the pandemic, have altered the balance of benefits and harms that informed current (pre-COVID-19) guideline recommendations for lung cancer screening and lung nodule evaluation. We developed consensus statements to guide clinicians managing lung cancer screening programs and patients with lung nodules during the COVID-19 pandemic. METHODS: An expert panel of 24 members, including pulmonologists (17), thoracic radiologists (5), and thoracic surgeons (2) was formed. The panel was provided with an overview of current evidence, summarized by recent guidelines related to lung cancer screening and lung nodule evaluation. The panel was convened by video teleconference to discuss then vote on statements related to 12 common clinical scenarios. A pre-defined threshold of 70% of panel members voting agree or strongly agree was used to determine if there was a consensus for each statement. Items that may influence decisions were listed as notes to be considered for each scenario. RESULTS: Twelve statements related to baseline and annual lung cancer screening (2), surveillance of a previously detected lung nodule (5), evaluation of intermediate and high risk lung nodules (4), and management of clinical stage I non-small cell lung cancer (1) were developed and modified. All 12 statements were confirmed as consensus statements by voting results. The consensus statements provide guidance about situations where it was felt to be appropriate to delay screening, defer surveillance imaging of lung nodules, and minimize non-urgent interventions during the evaluation of lung nodules and stage I non-small cell lung cancer. CONCLUSIONS: There was consensus that during the COVID-19 pandemic it is appropriate to defer enrollment in lung cancer screening and modify the evaluation of lung nodules due to the added risks from potential exposure and the need for resource reallocation. There are multiple local, regional, and patient related factors that should be considered when applying these statements to individual patient care."],"journal":"Chest","authors":["Mazzone, Peter J","Gould, Michael K","Arenberg, Douglas A","Chen, Alexander C","Choi, Humberto K","Detterbeck, Frank C","Farjah, Farhood","Fong, Kwun M","Iaccarino, Jonathan M","Janes, Samuel M","Kanne, Jeffrey P","Kazerooni, Ella A","MacMahon, Heber","Naidich, David P","Powell, Charles A","Raoof, Suhail","Rivera, M Patricia","Tanner, Nichole T","Tanoue, Lynn K","Tremblay, Alain","Vachani, Anil","White, Charles S","Wiener, Renda Soylemez","Silvestri, Gerard A"],"date":"2020-04-27T11:00:00Z","year":2020,"_id":"32335067","week":"202018|Apr 27 - May 03","doi":"10.1016/j.chest.2020.04.020","keywords":["covid-19","consensus statement","lung cancer screening","lung nodule"],"source":"PubMed","topics":["Prevention"],"weight":1,"locations":["thoracic","thoracic"],"_version_":1665172302024671232,"score":361.8304},{"pmid":32318706,"title":"Multicenter initial guidance on use of antivirals for children with COVID-19/SARS-CoV-2.","text":["Multicenter initial guidance on use of antivirals for children with COVID-19/SARS-CoV-2.","BACKGROUND: Although Coronavirus Disease 2019 (COVID-19) is mild in nearly all children, a small proportion of pediatric patients develops severe or critical illness. Guidance is therefore needed regarding use of agents with potential activity against severe acute respiratory syndrome coronavirus 2 in pediatrics. METHODS: A panel of pediatric infectious diseases physicians and pharmacists from 18 geographically diverse North American institutions was convened. Through a series of teleconferences and web-based surveys, a set of guidance statements was developed and refined based on review of best available evidence and expert opinion. RESULTS: Given the typically mild course of pediatric COVID-19, supportive care alone is suggested for the overwhelming majority of cases. The panel suggests a decision-making framework for antiviral therapy that weighs risks and benefits based on disease severity as indicated by respiratory support needs, with consideration on a case-by-case basis of potential pediatric risk factors for disease progression. If an antiviral is used, the panel suggests remdesivir as the preferred agent. Hydroxychloroquine could be considered for patients who are not candidates for remdesivir or when remdesivir is not available. Antivirals should preferably be used as part of a clinical trial if available. CONCLUSIONS: Antiviral therapy for COVID-19 is not necessary for the great majority of pediatric patients. For those rare children who develop severe or critical disease, this guidance offer an approach for decision-making regarding antivirals, informed by available data. As evidence continues to evolve rapidly, the need for updates to the guidance is anticipated.","J Pediatric Infect Dis Soc","Chiotos, Kathleen","Hayes, Molly","Kimberlin, David W","Jones, Sarah B","James, Scott H","Pinninti, Swetha G","Yarbrough, April","Abzug, Mark J","MacBrayne, Christine E","Soma, Vijaya L","Dulek, Daniel E","Vora, Surabhi B","Waghmare, Alpana","Wolf, Joshua","Olivero, Rosemary","Grapentine, Steven","Wattier, Rachel L","Bio, Laura","Cross, Shane J","Dillman, Nicholas O","Downes, Kevin J","Timberlake, Kathryn","Young, Jennifer","Orscheln, Rachel C","Tamma, Pranita D","Schwenk, Hayden T","Zachariah, Philip","Aldrich, Margaret","Goldman, David L","Groves, Helen E","Lamb, Gabriella S","Tribble, Alison C","Hersh, Adam L","Thorell, Emily A","Denison, Mark R","Ratner, Adam J","Newland, Jason G","Nakamura, Mari M","32318706"],"abstract":["BACKGROUND: Although Coronavirus Disease 2019 (COVID-19) is mild in nearly all children, a small proportion of pediatric patients develops severe or critical illness. Guidance is therefore needed regarding use of agents with potential activity against severe acute respiratory syndrome coronavirus 2 in pediatrics. METHODS: A panel of pediatric infectious diseases physicians and pharmacists from 18 geographically diverse North American institutions was convened. Through a series of teleconferences and web-based surveys, a set of guidance statements was developed and refined based on review of best available evidence and expert opinion. RESULTS: Given the typically mild course of pediatric COVID-19, supportive care alone is suggested for the overwhelming majority of cases. The panel suggests a decision-making framework for antiviral therapy that weighs risks and benefits based on disease severity as indicated by respiratory support needs, with consideration on a case-by-case basis of potential pediatric risk factors for disease progression. If an antiviral is used, the panel suggests remdesivir as the preferred agent. Hydroxychloroquine could be considered for patients who are not candidates for remdesivir or when remdesivir is not available. Antivirals should preferably be used as part of a clinical trial if available. CONCLUSIONS: Antiviral therapy for COVID-19 is not necessary for the great majority of pediatric patients. For those rare children who develop severe or critical disease, this guidance offer an approach for decision-making regarding antivirals, informed by available data. As evidence continues to evolve rapidly, the need for updates to the guidance is anticipated."],"journal":"J Pediatric Infect Dis Soc","authors":["Chiotos, Kathleen","Hayes, Molly","Kimberlin, David W","Jones, Sarah B","James, Scott H","Pinninti, Swetha G","Yarbrough, April","Abzug, Mark J","MacBrayne, Christine E","Soma, Vijaya L","Dulek, Daniel E","Vora, Surabhi B","Waghmare, Alpana","Wolf, Joshua","Olivero, Rosemary","Grapentine, Steven","Wattier, Rachel L","Bio, Laura","Cross, Shane J","Dillman, Nicholas O","Downes, Kevin J","Timberlake, Kathryn","Young, Jennifer","Orscheln, Rachel C","Tamma, Pranita D","Schwenk, Hayden T","Zachariah, Philip","Aldrich, Margaret","Goldman, David L","Groves, Helen E","Lamb, Gabriella S","Tribble, Alison C","Hersh, Adam L","Thorell, Emily A","Denison, Mark R","Ratner, Adam J","Newland, Jason G","Nakamura, Mari M"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32318706","week":"202017|Apr 20 - Apr 26","doi":"10.1093/jpids/piaa045","keywords":["covid-19","sars-cov-2","antiviral","guidance","pediatric"],"source":"PubMed","topics":["Treatment"],"weight":1,"locations":["North American"],"e_drugs":["remdesivir","Hydroxychloroquine"],"_version_":1664815087749169154,"score":330.1589}]}